PROVECTUS BIOPHARMACEUTICALS, INC. DEALER-MANAGER AGREEMENT January , 2017Dealer-Manager Agreement • January 26th, 2017 • Provectus Biopharmaceuticals, Inc. • Pharmaceutical preparations • New York
The following (this “Agreement”) will confirm our agreement relating to the proposed rights offering (the “Rights Offering”) to be undertaken by Provectus Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), pursuant to which the Company will distribute to holders of record of its common stock, par value $0.001 per share (the “Common Stock”), and holders of the Company’s class of warrants with an exercise price of $0.85 per share expiring June 19, 2020 (“Listed Warrants”) subscription rights (the “Rights”) to purchase up to an aggregate of 19,662,782 units (the “Units”), each Unit consisting of four shares of Common Stock (the “Rights Shares”) and one-half a share of Series C Convertible Preferred Stock (the “Preferred Stock”), at a subscription price of $ per Unit in cash (the “Subscription Price”). The Subscription Price is subject to decrease by up to 20% by the Company after consultation with the Dealer-Manager, as described in the Prospectus (as defined herein).
WARRANT AGENCY AGREEMENTWarrant Agency Agreement • January 26th, 2017 • Provectus Biopharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
WARRANT AGENCY AGREEMENT (“Agency Agreement”) made as of January [●], 2017 (“Issuance Date”), between Provectus Biopharmaceuticals, Inc., a Delaware corporation, with offices at 7327 Oak Ridge Highway, Suite A, Knoxville, Tennessee 37931 (the “Company”), and Broadridge Corporate Issuer Solutions, Inc., with offices at 1717 Arch Street, Suite 1300, Philadelphia, Pennsylvania 19103 (the “Warrant Agent”).
